Kevin Watson, MD
Pulmonary Disease · New Britain, CTNPI 1205891280
Payments from drug & device makers
Across 163 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Novartis$274
- Genentech USA, Inc.$138
- Harmony Biosciences LLC$134
- Grifols USA, LLC$124
- Mallinckrodt Hospital Products Inc.$112
- plus $650 from 17 others
What the payments were for
- Food & beverage$2,94093%
- Education$2207%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 101 | $1,728 |
| Novartis | 20 | $274 |
| Genentech USA, Inc. | 8 | $138 |
| Harmony Biosciences LLC | 4 | $134 |
| Grifols USA, LLC | 1 | $124 |
| Mallinckrodt Hospital Products Inc. | 2 | $112 |
| Insmed, Inc. | 4 | $90 |
| Regeneron Healthcare Solutions, Inc. | 1 | $80 |
| Amgen | 2 | $65 |
| AstraZeneca | 4 | $59 |
| ZOLL Respicardia, Inc. | 1 | $54 |
| CSL Behring | 3 | $48 |
| Pulmonx Corporation | 2 | $40 |
| Shire North American Group Inc | 1 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Boehringer Ingelheim | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Mylan Specialty L.p. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Pfizer | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Philips North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolastin-C$124
How this compares
$3,160 in reported general payments places this provider in the 60th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 31 | $433,653 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 441 | $427,636 |
| Spiriva RespimatTiotropium Bromide | 219 | $199,770 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 219 | $160,787 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 215 | $154,725 |
| Fasenra PenBenralizumab | 24 | $150,543 |
| Breo ElliptaFluticasone/Vilanterol | 251 | $149,820 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 139 | $110,406 |
| NucalaMepolizumab | 16 | $57,809 |
| Dupixent PenDupilumab | 13 | $56,132 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 63 | $42,171 |
| SymbicortBudesonide/Formoterol Fumarate | 81 | $31,178 |
| EliquisApixaban | 39 | $26,283 |
| Incruse ElliptaUmeclidinium Bromide | 49 | $22,908 |
| DuleraMometasone/Formoterol | 45 | $19,825 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Incruse Ellipta | $1,728 | $825,5611,011 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $26 | $786,001452 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $59 | $203,888319 claims |
| PfizerEliquis | $17 | $26,28339 claims |
| MerckDulera | $18 | $19,82545 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in New Britain
- Mircea BadaraNew Britain$1M
- Geoffrey ChuppNew Haven$3.1M
- Jonathan KoffNew Haven$1.1M
- Naftali KaminskiNew Haven$1M
- Danielle Antin-OzerkisNew Haven$1M
- Mridu GulatiNew Haven$536K
- Phillip JosephNew Haven$488K
- Tapas BandyopadhyayWest Hartford$483K
- Raj ParikhHartford$419K
- Patrick TroyHartford$385K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.